News & Videos - KERYX BIOPHARMACEUTICALS INC. - English

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Akebia Therapeutics, Inc. (“Akebia” or “the Company”) (NASDAQ: AKBA ) who formerly held shares of Keryx Biopharmaceuticals, Inc. (KERX) for violations of the securities laws. If you are a shareholder, click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA...

Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Keryx Biopharmaceuticals, Inc. In The U.S. District Court For The District Of Delaware PR Newswire NEW YORK, Nov. 5, 2018 NEW YORK , Nov. 5, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the District of Delaware , Case No.1:18-cv-01589-LPS, on behalf of public common shareholders of Keryx Biopharmaceuticals, Inc....

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Keryx Biopharmaceuticals, Inc. - KERX PR Newswire NEW YORK, Oct. 1, 2018 NEW YORK , Oct. 1, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City , is investigating Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NasdaqCM:KERX) relating to the sale of the Company to Akebia...

RADNOR, PA / ACCESSWIRE / September 10, 2018 / Kaskela Law LLC is investigating Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NASDAQ: KERX) on behalf of the Company's stockholders. In 2017, a shareholder class action complaint was filed against the Company in federal court on behalf of certain purchasers of Keryx's common stock. Among other things, the shareholder complaint alleged that Keryx and certain of the Company's senior executive officers violated the federal securities laws...

WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc. PR Newswire NEW YORK, June 29, 2018 NEW YORK , June 29, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Keryx Biopharmaceuticals Inc. ("KERX" or the "Company") (NASDAQ: KERX) in connection with the proposed acquisition of the Company by Akebia Therapeutics, Inc. ("AKBA") (NASDAQ: AKBA). Under the terms of the acquisition agreement, KERX...

...

NEW YORK, NY / ACCESSWIRE / November 6, 2017 / Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 6, 2017 at 5:00 PM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/22003 . To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About Investor...

NEW YORK, NY / ACCESSWIRE / August 3, 2017 / Kimball Electronics, Inc. (NASDAQ: KE ) will be discussing their earnings results in their Q4 Earnings Call to be held on Thursday, August 3, 2017 at 10:00 AM Eastern Time. To listen to the event live - visit https://www.investornetwork.com/company/21999 . Replay Information The replay will be available online at https://www.investornetwork.com/company/21999 . About Investor Network Investor Network (IN) is a new financial content community, serving...

NEW YORK, NY / ACCESSWIRE / May 4, 2017 / Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX ) will be discussing their earnings results in their Q1 Earnings Call to be held May 4, 2017 at 8:00 AM Eastern Time. To listen to the event live - visit https://www.investornetwork.com/company/22003 . Replay Information The replay will be available online at https://www.investornetwork.com/company/22003 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of...

NEW YORK, NY / ACCESSWIRE / May 2, 2017 / Kimball Electronics, Inc. (NASDAQ: KE) will be discussing their earnings results in their Q3 Earnings Call to be held May 2, 2017 at 10:00 AM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/21999 . Replay Information The replay will be available online at https://www.investornetwork.com/company/21999 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of unique...

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Keryx Biopharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire NEW YORK, March 7, 2016 NEW YORK , March 7, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). If you are...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

BOSTON, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced the publication of results from its pivotal Phase 3 study evaluating ferric citrate for iron deficiency anemia (IDA) in non-dialysis-dependent chronic kidney disease (NDD-CKD) in the online issue of the Journal of the American Society of Nephrology (JASN). Ferric citrate (Auryxia®) is currently...

Enters 2017 with positive momentum for Auryxia® (ferric citrate) in dialysis; preliminary unaudited fourth quarter net U.S. product sales of $8.2 million Submitted supplemental new drug application (sNDA) seeking Auryxia label expansion to treat iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease Expands management’s operational and strategic expertise with the appointment of two executives SAN FRANCISCO, Jan. 08, 2017 (GLOBE NEWSWIRE) -- Keryx...

BOSTON, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the 35 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11 at 2:30 p.m. PST (5:30 p.m. EST). A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor...

CHICAGO, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced case study data, which showed that Auryxia® (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis. These data were presented in a poster presentation today at the American Society of Nephrology’s 2016 Kidney Week taking place in...

Pivotal Phase 3 data showed the potential of Ferric Citrate (Auryxia®) to treat IDA in adults with NDD-CKD Phase 3 trial results support supplemental new drug application (sNDA) seeking to expand Auryxia’s label CHICAGO, Nov. 17, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, announced presentation of additional data from its pivotal Phase 3 study for iron deficiency...

BOSTON, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that the U.S. Food and Drug Administration (FDA) has approved its application for a second drug product contract manufacturer. Patheon Manufacturing Services LLC of Greenville, North Carolina, a leading global provider of pharmaceutical manufacturing services, is now an FDA approved drug product...

The company has established adequate supply of Auryxia ® (ferric citrate) and is prepared to make this medicine available to people on dialysis pending U.S. FDA approval of second contract manufacturer Keryx has completed the sNDA (supplemental new drug application) seeking to expand Auryxia’s label and will submit it pending final U.S. FDA agreement on the company’s proposed pediatric plan BOSTON, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a...

BOSTON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Stifel 2016 Healthcare Conference on Tuesday, November 15 at 1:30 p.m. Eastern Time. A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under...